About the Event
Germany ranks fourth globally in biopharmaceuticals, with over 650 biotechnology companies. Biologics Manufacturing Germany 2025 will delve into advancements in biomanufacturing and examine how rising operational complexity and uncertainty impact long-term decision-making. Topics will include risk mitigation, regulatory changes, and CMO partner selection, especially in light of automation, AI, and sustainability. These discussions are crucial for stakeholders in the biologics manufacturing industry, providing valuable insights on navigating challenges and making informed decisions in a complex and dynamic environment.
WuXi Advanced Therapies will be in attendance and would be happy to meet!